Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

(2013) J. Guedj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

(2012) Yoshiyasu Karino et al.   JOURNAL OF HEPATOLOGY

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

(2012) Stanislas Pol et al.   LANCET INFECTIOUS DISEASES

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

(2011) Richard E. Nettles et al.   HEPATOLOGY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

(2010) E Snoeck et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants

(2010) Bambang S. Adiwijaya et al.   PLoS Computational Biology